NeuroSense Unveils Significant Progress for ALS Treatment PrimeC in 2025
NeuroSense Therapeutics has announced substantial advancements during the first half of 2025, marking a transformative period for the late-stage clinical biotechnology company as it progresses its novel…
Peel Hunt Reaffirms Add Rating for hVIVO Stock Amid Market Insights
Leading pharmaceutical service provider hVIVO (HVO) is once again in the spotlight as prominent financial analysts reiterate their positive outlooks, underscoring confidence in the company’s market position…
Compass Pathways’ Psilocybin Therapy Shines in Q2, Clinical Milestones Achieved
Compass Pathways, a pioneering clinical-stage mental health company, has marked its second quarter of 2025 with significant advancements, most notably a robust clinical update for its lead…
Revolutionary Blood Test Trial for 10 Cancers Achieves Major Milestone
A groundbreaking clinical trial evaluating a revolutionary blood test for the early detection of multiple cancers has achieved a significant milestone in the United Kingdom. The MODERNISED…
Eli Lilly’s Mounjaro Shows Significant Heart Benefits in Diabetes Trial
Eli Lilly’s blockbuster diabetes drug, Mounjaro, has demonstrated significant cardiovascular health benefits in a pivotal late-stage clinical trial, directly comparing its efficacy with the company’s established treatment,…
FDA Fast Tracks Ateganosine for Non-Small Cell Lung Cancer Treatment
In a significant development for oncology, the U.S. Food and Drug Administration (FDA) has granted fast track designation to ateganosine, a novel therapeutic agent, specifically targeting non-small…